Dazdotuftide TFA
Dazdotuftide TFA (TRS01 TFA) is a multi-target immunomodulator composed of tuftsin and phosphorylcholine-related groups. Dazdotuftide TFA regulates TLR4/NF-κB and NRP1/VEGF165 related signaling pathways and inhibits the production of pro-inflammatory cytokines. Dazdotuftide TFA can be used in studies related to inflammation and immunoregulation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2522933-45-3
- Formule: C43H68N13O13P.xC2HF3O2
- Masse moléculaire:1006.05 (free base)
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
TLR4 |
NRP1 |
In Vitro
Dazdotuftide TFA (TRS01 TFA) reduces the production of IL-1β, IL-2, IL-5, IL-6, IL-9, IL-12 (p70), IL-13, IL-17A, IL-18, IL-21, IL-22, IL-23, IFNγ, TNFα and GM-CSF in CD3/CD28-activated human PBMCs, with negligible effects on cell viability.[1]
Dazdotuftide TFA reduces the production of IL-1β, IL-6, IL-13 and IL-17A, and decreases CD68 gene expression in inflammatory human temporal artery biopsies[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2522933-45-3
-
Masse moléculaire 1006.05 (free base)
-
Formule C43H68N13O13P.xC2HF3O2
-
Synonyms
TRS01 TFA
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Vofo BN, et al. Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate. Biomedicines. 2023 May 27;11(6):1562. [Content Brief]
[2]. Tungsattayathitthan U, et al. Emerging therapeutic targets in non-infectious uveitis and scleritis. Frontiers in medicine. 2026;13:1846374. [Content Brief]
[3]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dazdotuftide TFA Related Classifications
HY-P3449A Related Classifications
Powered by Bioz